Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xingnao Jianshen prescription is a Traditional Chinese Medicine (TCM) herbal compound developed by the Affiliated Hospital of Changchun University of Traditional Medicine for the treatment of acute ischemic stroke. It is specifically indicated for patients exhibiting the 'phlegm-heat fu-organ' pattern, a specific diagnostic category in TCM. The prescription is typically administered as an adjunct to standard Western medical therapy. Clinical evaluation focuses on improvements in neurological function (NIHSS), activities of daily living (Barthel Index), and overall disability (modified Rankin Scale). Preclinical research utilizes HPLC/MS-MS and transcriptomics in rat models of middle cerebral artery occlusion (MCAO) to investigate its multi-target pharmacodynamic mechanisms, which likely involve neuroprotection and modulation of the inflammatory response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xingnao Jianshen prescription.